- Reaction score
- 495
i ordered 0.5 % pyri from here : https://actifolic.com/product/pyrilutamide/
will receive it tomorrow
will receive it tomorrow
That's expensivei ordered 0.5 % pyri from here : https://actifolic.com/product/pyrilutamide/
will receive it tomorrow
bruh i would literally pay anything i have to keep my hair. i just hope it worksThat's expensive
in the study they used 2.5 mg and 5 mgI think in the study they used between 2,5% and 5%.
Can anyone confirm?
Ah ok, so you are using the maximum quantity. Are you taking more things, like finas? To check if you have positive results.
Can you post a before picture?No, pyri is the only thing I’m taking
We salute youin the study they used 2.5 mg and 5 mg
so 0.5% concentration is 5 mg/mL
i just applied half a mL to test the waters. i'm not dead yet which is nice
i ordered 0.5 % pyri from here : https://actifolic.com/product/pyrilutamide/
will receive it tomorrow
1 month if you use 1ml every day.How long the flask last ?
i ordered 0.5 % pyri from here : https://actifolic.com/product/pyrilutamide/
will receive it tomorrow
no need for dutasteride because pyri basically does as good with no side effects. it would be interesting to see what a superior dose yields in terms of resultsThis and dutasteride and you will never have to worry about hairloss again basically.
Thank you for all the information. Really appreciated.KX-826 Phase 2 Results
Purpose
The purpose of this study is to evaluate the safety, exposure, and efficacy of flecainide (KX-826) in the treatment of adult men with androgenetic alopecia (Androgenetic Alopecia) in China.
The objective of this study is to evaluate the safety, population exposure and efficacy of forretinoin (KX-826) in the treatment of adult male patients with Androgenetic Alopecia in China and to determine the recommended dose for a phase II trial.
Methods
This is a multicenter, randomized, two-word, placebo-controlled phase I clinical trial (KX-826-CN-1002).
The study is a phase I clinical trial (KX-826-CN-1002). Chinese adult men with Androgenetic Alopecia who met the Hamilton-Norwood classification (Class IIV, IV, YV) were randomized in a 1:1:1:1 ratio to the KX-826-CN-1002.
The patients were randomly assigned to the KX-826 2.5 mg (0.25% concentration) BID group, the 5 mg (0.5% concentration) QD group, the 5 mg (0.5% concentration)
BID group and the anandamide group (QD and BID groups).
The study design and efficacy endpoints are shown in Figure 1.
Figure 1 Study design and efficacy endpoints
Male, >18 years of age, in good general health
Clinical diagnosis of androgenic baldness; severity of baldness according to Hamilton-Norwood grading IIv, IV, YV
"Willingness to use the same shampoo and maintain the same hair shape, color, and length throughout the trial
"No parenting plan during the study period and within 3 months of the last dose and able to use effective contraception
Efficacy Endpoints:
* Primary endpoint; mean change from baseline in the target area of non-compulsory hair count (TAHC) after 24 weeks of treatment
* Secondary endpoints: change from baseline in TAHC after 6, 12, and 18 weeks of treatment; change from baseline in non-compassionate hair diameter (TAHW) in target area after 6, 12, 18, and 24 weeks of treatment
Change from baseline in TAHW; Hair growth assessment (HGA), including subject self-assessment, investigator assessment, and
Third-party physician assessment
Baseline patient characteristics
120 Chinese adult male Androgenetic Alopecia patients (mean height: 172.95 cm; mean weight: 75.05 kg), randomly assigned to
KX-826 2.5 mg (0.25% concentration) BID group (n=30), 5 mg (0.5% concentration) QD group (n=30), 5 mg (0.5% concentration)
(0.5% concentration) BID" (n=30) group, placebo QD group (n=10) and placebo BID group (n=20), with details of the patients
The baseline characteristics are shown in Table 1.
Security Analysis
*. Systemic exposure to KX-826 and its metabolite KX-982 reached steady-state after 14 days of topical application; transdermal blood concentrations were low in all dose groups.
The drug concentrations were low, with detectable KX-826 blood levels ranging from 0.3-4.1 ng/mL and KX-982 blood levels ranging from 0.4-10.4 ng/mL.
The blood levels of KX-982 were 0.4-10.4 ng/mL. The three dose reductions due to adverse events (AEs) were classified as Grade 1 contact dermatitis, Grade 2 rash, and Grade 1 smoldering rash according to the Common Adverse Event Evaluation Criteria 5.0.
Grade 1 rash and Grade 1 itch.
The incidence of adverse drug reactions (ADRs) was 16.1%, with the most common ADR being cancer itch (5.9%), followed by contact dermatitis (2.5%); and 1 ADR (2.5%).
The most common ADR was carcinoma itch (5.9%), followed by contact dermatitis (2.5%); one case had grade 3 hypertriglyceridemia and one case had grade 4 hypertriglyceridemia, but the baseline triglyceride value was high (6.99 mmolL).
(6.99 mmolL).
No serious adverse events, no serious ADRs and no deaths.
Conclusion
* Chinese adult male Androgenetic Alopecia patients (Hamilton-Norwood classification IIv, IV, YV) treated with topical KX-826 5 mg BID
After 24 weeks of treatment, there was a significant increase in TAHC in the target area compared to placebo, and the overall safety of the KX-826 dose groups was good.
No new safety events were observed outside of the expected period. In the 5 mg (0.5% concentration) BID group, TAHC increased by 15.34 roots/cm?at week 24 compared to the placebo group.
There was a statistically significant difference (p = 0.024).
The difference was statistically significant (p = 0.024). KX-826 5 mg BID is recommended as the dose for confirmatory clinical trials.
Exactly my thought. A combination of finasteride and this and you should really be able to stop dht getting to your follicles.This and dutasteride and you will never have to worry about hairloss again basically.
In worst case scenario this is as effective as finasteride and might be near dutasteride efficiency if you dose it high enough. 15.34/cm2 increase is compared to placebo also, not baseline. 5mg bid group had ~23/cm2 increase which is as mentioned earlier as strong as dutasteride.
But thing is antiandrogen response are dose dependant. So dosed right you could use it without 5ar inhibitor.